Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.41 -0.3%	$19.14	$13.40 ▼ $25.23	$3.76B	0.65	1.95 million shs	1.23 million shs
MRUS Merus	$54.13 +2.6%	$48.25	$33.19 ▼ $62.98	$3.65B	1.04	752,516 shs	644,395 shs
NTLA Intellia Therapeutics	$9.57 +3.7%	$8.41	$5.90 ▼ $28.18	$956.07M	2.14	2.90 million shs	5.29 million shs
SWTX SpringWorks Therapeutics	$46.96 0.0%	$45.50	$28.21 ▼ $62.00	$3.54B	0.7	2.48 million shs	2.32 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.31%	-1.71%	+1.96%	+31.59%	+41.12%
MRUS Merus	+2.64%	+1.98%	-1.83%	+21.78%	-4.88%
NTLA Intellia Therapeutics	+3.68%	-0.10%	+4.48%	+15.16%	-61.72%
SWTX SpringWorks Therapeutics	-0.02%	+0.21%	+1.03%	+1.03%	+30.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.8274 of 5 stars	3.3	1.0	0.0	3.2	4.2	2.5
MRUS Merus	3.3835 of 5 stars	4.6	3.0	0.0	2.1	2.5	0.0
NTLA Intellia Therapeutics	4.38 of 5 stars	4.3	1.0	4.7	1.8	2.5	0.6
SWTX SpringWorks Therapeutics	1.4982 of 5 stars	3.1	2.0	0.0	2.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$27.64	23.35% Upside
MRUS Merus	3.14	Buy	$84.64	56.36% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	248.68% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.95% Upside

Current Analyst Ratings Breakdown

Latest NTLA, ACAD, MRUS, and SWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.92	$0.70 per share	31.89	$4.40 per share	5.09
MRUS Merus	$36.13M	103.69	N/A	N/A	$9.46 per share	5.72
NTLA Intellia Therapeutics	$57.88M	17.13	N/A	N/A	$8.56 per share	1.12
SWTX SpringWorks Therapeutics	$191.59M	18.47	N/A	N/A	$6.47 per share	7.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.36	29.49	4.81	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)

Latest NTLA, ACAD, MRUS, and SWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
MRUS Merus	N/A	5.86	5.86
NTLA Intellia Therapeutics	N/A	4.90	4.90
SWTX SpringWorks Therapeutics	N/A	4.33	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
MRUS Merus	96.14%
NTLA Intellia Therapeutics	88.77%
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
MRUS Merus	4.57%
NTLA Intellia Therapeutics	3.10%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	120.00 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable

NTLA, ACAD, MRUS, and SWTX Headlines

Recent News About These Companies

SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat

June 24 at 6:40 PM | msn.com

SG Americas Securities LLC Buys 9,409 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 21, 2025 | marketbeat.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat as Potential First Treatment for Desmoid Tumors in the EU

June 20, 2025 | quiverquant.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

June 20, 2025 | globenewswire.com

GAMMA Investing LLC Buys 13,270 Shares of SpringWorks Therapeutics (NASDAQ:SWTX)

June 19, 2025 | marketbeat.com

Comparing SpringWorks Therapeutics (NASDAQ:SWTX) & Genenta Science (NASDAQ:GNTA)

June 18, 2025 | americanbankingnews.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts

June 17, 2025 | marketbeat.com

Biotech Stocks To Consider - June 16th

June 16, 2025 | marketbeat.com

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading Volume - Here's Why

June 16, 2025 | marketbeat.com

FNY Investment Advisers LLC Purchases New Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 16, 2025 | marketbeat.com

Assenagon Asset Management S.A. Takes $3.52 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 16, 2025 | marketbeat.com

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase - What's Next?

June 9, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLC

June 5, 2025 | marketbeat.com

RFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

Nuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 31, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 28, 2025 | marketbeat.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 27, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA, ACAD, MRUS, and SWTX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.41 -0.07 (-0.31%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$22.54 +0.14 (+0.60%)

As of 08:04 AM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Merus NASDAQ:MRUS

$54.13 +1.39 (+2.64%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$54.38 +0.25 (+0.46%)

As of 08:09 AM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Intellia Therapeutics NASDAQ:NTLA

$9.57 +0.34 (+3.68%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$9.72 +0.15 (+1.62%)

As of 08:00 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

SpringWorks Therapeutics NASDAQ:SWTX

$46.96 -0.01 (-0.02%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$46.96 0.00 (0.00%)

As of 08:11 AM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time